Investments - Narrative (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Dec. 31, 2021	Apr. 30, 2020	Mar. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Impairment due to credit losses				$ 0	$ 0
Cash received from sale of subsidiary	$ 12,900,000
Equity method investment, realized gain (loss) on disposal			$ 12,900,000	$ 0	$ 0	$ 12,888,000
Navitor Pharmaceuticals, Inc.
Variable Interest Entity [Line Items]
Threshold for development costs payments		$ 50,000,000
Collaborative arrangement, payment for one time fee		10,000,000
Collaborative arrangement, upfront development costs		25,000,000
Navitor Pharmaceuticals, Inc. | Minimum
Variable Interest Entity [Line Items]
Collaborative arrangement, expected development costs		410,000,000
Navitor Pharmaceuticals, Inc. | Maximum
Variable Interest Entity [Line Items]
Collaborative arrangement, expected development costs		475,000,000
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Investments		$ 15,000,000
Ownership percentage		13.00%